Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.70 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.70 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.70 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.56 |
| ▸ | PARP1 | P09874 | 2/20 | 0.53 |
| ▸ | SLC9A1 | P19634 | 6/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | TNKS | O95271 | 1/20 | 0.43 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15748237 | 0.82 | HTR2A (1.00) | HTR2AADRA1DADRA1BP2RX7HTR1A | |
| Hydrochloric Acid SCHEMBL25342544 | 0.81 | HTR2A (1.00) | HTR2AADRA1DADRA1BP2RX7HTR1A | |
| Hydrochloric Acid SCHEMBL29432933 | 0.81 | HTR2A (1.00) | HTR2AADRA1DADRA1BP2RX7HTR1A | |
| SCHEMBL15748197 | 0.81 | DRD2 (0.61) | HTR2AADRA1DADRA1BP2RX7PARP1 | |
| SCHEMBL15748104 | 0.80 | HTR2A (0.64) | HTR2AADRA1DADRA1BP2RX7HTR1A | |
| SCHEMBL17103031 | 0.79 | HTR2A (0.63) | HTR2AADRA1DADRA1BP2RX7SLC9A1 | |
| SCHEMBL8416308 | 0.77 | P2RX7 (0.61) | HTR2AADRA1DADRA1BP2RX7SLC9A1 | |
| SCHEMBL15748082 | 0.76 | P2RX7 (0.60) | HTR2AADRA1DADRA1BP2RX7SLC9A1 | |
| SCHEMBL15748164 | 0.75 | HTR2A (0.78) | HTR2AADRA1DADRA1BP2RX7HTR1A | |
| SCHEMBL1545365 | 0.75 | PARP1 (0.54) | HTR2APARP1HTR1ADRD2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9415047-B2 | Use of benzo five-membered nitrogen heterocyclic piperazine or piperidine derivatives | Liaoning Emmy Biological Pharmaceutical Co., Ltd. (CN) | 2016-08-16 | — | — | US | disclosed |
| US-9415047-B2 | Use of benzo five-membered nitrogen heterocyclic piperazine or piperidine derivatives | Liaoning Emmy Biological Pharmaceutical Co., Ltd. (CN) | 2016-08-16 | — | — | US | disclosed |
| US-20150297586-A1 | USE OF BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERAZINE OR PIPERIDINE DERIVATIVES | Liaoning Emmy Biological Pharmaceutical Co., Ltd. (CN) | 2015-10-22 | — | — | US | disclosed |
| US-20150297586-A1 | USE OF BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERAZINE OR PIPERIDINE DERIVATIVES | Liaoning Emmy Biological Pharmaceutical Co., Ltd. (CN) | 2015-10-22 | — | — | US | disclosed |
| EP-2924033-A1 | USE OF BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERAZINE OR PIPERIDINE DERIVATIVES | Liaoning Emmy Biological Pharmaceutical Co., Ltd (CN) | 2015-09-30 | — | — | EP | disclosed |
| WO-2014079155-A1 | USE OF BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERAZINE OR PIPERIDINE DERIVATIVES | 辽宁贝雷生物制药有限公司 (CN) | 2014-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297586-A1 | USE OF BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERAZINE OR PIPERIDINE DERIVATIVES | P2RX5, TBXA2R, CYP3A5 | HTR2A 353/4885ADRA1D 82/4885ADRA1B 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.